SRRK

Scholar Rock has shifted from a clinical‑only story to one where near‑term value is driven primarily by manufacturing/regulatory execution (FDA reinspection, fill/finish remediation, and resubmission timing) and the company's ability to secure non‑punitive financing if approval is delayed; monitor resubmission date, Novo reinspection outcome, cash burn versus guidance, and any royalty/debt deal terms as the key catalysts that will make or break the current valuation. If the company validates commercial supply and obtains timely approval without heavy equity dilution, upside is large; prolonged remediation, failed reinspection, or dilutive financing materially reduces fair value.